Targeting All BRAF Alterations: The (Re)-Search Continues
JCO Precision Oncology · 2024-02 · (8)
DOI: 10.1200/po.23.00670 ↗Kurz gefasst
Editorial in der Zeitschrift JCO Precision Oncology, 2024-02. Verfasst von Deepak Bhamidipati und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
VivekSubbiah & colleagues delve into the @ASCO #TAPURStudy, shedding light on the importance of targeting ALL #BRAFAlterations, beyond V600E. (Re)-search continues, urging us to push the boundaries and unlock new possibilities in #PrecisionMedicine. #CancerResearch #JCOPO
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Sarah Cannon Research Institute, Nashville, TN.
ORCID-Profile: Deepak Bhamidipati, Andrew Pellatt, Vivek Subbiah
Zitieren
APA
Bhamidipati, D., Pellatt, A., & Subbiah, V. (2024). Targeting All BRAF Alterations: The (Re)-Search Continues. JCO Precision Oncology. https://doi.org/10.1200/po.23.00670
Vancouver
Bhamidipati D, Pellatt A, Subbiah V. Targeting All BRAF Alterations: The (Re)-Search Continues. JCO Precision Oncology. 2024. doi:10.1200/po.23.00670
BibTeX
@article{Bhamidipati2024,
author = {Bhamidipati, Deepak and Pellatt, Andrew and Subbiah, Vivek},
title = {Targeting All BRAF Alterations: The (Re)-Search Continues},
journal = {JCO Precision Oncology},
year = {2024},
number = {8},
doi = {10.1200/po.23.00670}
}
EUVIMED